Widely used:Recently Viewed
Clear All
Value Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
₹32,040 Cr
63.89
7.08
43.68
0.03
13.18 %
15.55 %
0.16 %
112.45
11.87
₹5,625.80 Cr
₹5,916.50 Cr
₹3,527.30 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Syngene Intl
| -7.26 | -5.52 | -4.87 | 16.88 | 10.04 | 21.15 | -- |
|
BSE Healthcare
| -6.57 | -4.26 | -1.20 | 27.90 | 19.99 | 24.50 | 10.53 |
|
BSE Mid Cap
| -7.91 | -7.69 | -7.53 | 14.68 | 19.63 | 22.16 | 14.85 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Syngene Intl
| 20.95 | 19.79 | -5.54 | -1.97 | 98.45 | 14.86 | 2.25 |
|
BSE Mid Cap
| 25.84 | 45.53 | 1.38 | 39.18 | 19.87 | -3.05 | -13.31 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
--
--Min --Median --Max
--
--Min --Median --Max
--
Earnings Yield (%) = EBIT / Enterprise value
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1,450.10 | 40,836.86 | -- | -24.45 | |
| 602.65 | 32,422.56 | 161.9 | 4.86 | |
| 233.05 | 30,889.93 | 681.45 | 1.52 | |
| 1,004.20 | 25,595.23 | 105.28 | 12.07 |
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, Japan, Europe, the United States, and internationally. The company provides discovery chemistry services, such as... synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, clinical data management, regulatory, biostatistics, and medical writing services. Further, it offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited. Read more
1993
Kiran Mazumdar - Shaw
Jonathan Hunt
Bengaluru, Karnataka
Looking for more details about Syngene International Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Syngene International Ltd stood at ₹ 6,136 Cr as on 31-Dec-24
The share price of Syngene International Ltd is ₹796.10 (NSE) and ₹795.95 (BSE) as of 24-Jan-2025 IST. Syngene International Ltd has given a return of 10.04% in the last 3 years.
Syngene International Ltd has a market capitalisation of ₹ 32,040 Cr as on 24-Jan-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Syngene International Ltd is 7.08 times as on 24-Jan-2025, a 78% premium to its peers’ median range of 3.98 times.
The P/E ratio of Syngene International Ltd is 63.89 times as on 24-Jan-2025, a 46% premium to its peers’ median range of 43.68 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Syngene International Ltd and enter the required number of quantities and click on buy to purchase the shares of Syngene International Ltd.
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, Japan, Europe, the United States, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, clinical data management, regulatory, biostatistics, and medical writing services. Further, it offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
The promoter of Syngene International Ltd is BIOCON LIMITED. BIOCON LIMITED owns 52.46 per cent of the total equity. The chairman of the company is Kiran Mazumdar - Shaw , and the managing director is Jonathan Hunt..
There is no promoter pledging in Syngene International Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
40,837
|
|
|
32,423
|
|
|
30,890
|
|
|
25,595
|
| Syngene International Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
11.04
|
|
Operating margin(%)
|
16.14
|
|
Net Margin(%)
|
13.87
|
|
Dividend yield(%)
|
0.16
|
Yes, TTM profit after tax of Syngene International Ltd was ₹502 Cr.
₹-50.90
(
